Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937859 · ClinicalTrials.gov registry record · Phase 3
Treatment of Patients With Nocturia
A Phase 3 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
NCT00937859: Completed Phase 3 study, sponsored by Serenity Pharmaceuticals.
NCT00937859 is a Phase 3 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 301 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937859, a Phase 3 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
Primary Outcome
Change was calculated as the mean number of nocturic episodes per night during the last week of treatment minus the mean number of nocturic episodes at baseline
Interventions
- DRUG Placebo
- DRUG SER120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
What the finished NCT00937859 record still lists
NCT00937859 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00937859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00937859 about?
NCT00937859 is a clinical study titled "Treatment of Patients With Nocturia". The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
What is the current status of trial NCT00937859?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2009-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00937859?
The interventions under investigation include: Placebo (DRUG), SER120 (DRUG).
Who is sponsoring clinical trial NCT00937859?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00937859's enrollment target sits among peer trials
301 1121st of 2000 higher than 879 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia